New hope for kids with Tough-to-Treat neuroblastoma?
NCT ID NCT02308527
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy helps children with neuroblastoma that has returned or not responded to treatment. The trial enrolled 225 children aged 1 to 21. Researchers looked at tumor shrinkage and how long the disease stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin) plus chemotherapy (temozolomide, irinotecan, or topotecan)
What this could lead to
If successful, this combination could offer a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong
This is a phase 2 trial, so results are still preliminary. The added drugs may increase side effects without improving outcomes, and not all children will respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital des Enfants
Toulouse, 31059, France
-
Instituto de Investigacion Sanitaria
Valencia, 46026, Spain
-
Natasha van Eijkelenburg
Utrecht, Netherlands
-
Ospedale Pediatrico Bambino Gseu
Rome, 00165, Italy
-
Our Ladys Children's Hospital Dublin
Dublin, Dublin 12, Ireland
-
St Anna Children's Hospital and CCRI/Studies and Statistics
Vienna, A-1090, Austria
-
Swiss Paediatric Oncology Group
Bern, 3008, Switzerland
-
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Sutton, Surrey, SM2 5PT, United Kingdom
-
University Hospital
Ghent, Belgium
-
University Hospital Rigshospitalet
Copenhagen, DK-2100, Denmark